Wang Yangshuo, Zhou Jingru, Fan Cungang, Wang Dongliang, Jiao Feng, Liu Bo, Zhang Qingjun
Department of Neurosurgery, Peking University People's Hospital, Beijing, China.
Department of Neurosurgery, Peking University People's Hospital, Beijing, China.
J Clin Neurosci. 2017 Apr;38:79-83. doi: 10.1016/j.jocn.2016.12.001. Epub 2016 Dec 28.
Antithrombotic agents (AT), including anticoagulants and antiplatelets, are risk factors of chronic subdural hematomas (CSDHs). However, the use of AT has not been clearly associated with postoperative recurrence (PR) in the literature before. Furthermore, the association between the resumption of AT and postoperative complications also requests research. Databases including Pubmed, Embase and Cochrane were searched for patients presenting with CSDH on anticoagulant or antiplatelet medication. Ten studies were included to analyze the association between the use of AT and PR: The meta-analysis showed that the use of AT, both anticoagulants (OR=2.20, 95%CI [1.45, 3.33]; P=0.0002) and antiplatelets (OR=1.64, 95%CI [1.17, 2.30]; P=0.004), could increase the PR rate. Two studies were included to analyze the relationship between the resumption of AT and postoperative complications. The meta-analysis showed that after the patients on AT resumed their medication, the risk of PR did not increase (OR=0.33, 95%Cl [0.13, 0.80]; P=0.01), and the occurrence of thromboembolism events had no statistical significance (OR=1.30, 95%CI [0.26, 6.50]; P=0.75). This meta-analysis demonstrated that AT were risk factors for the recurrence of CSDH. Recommencement of AT did not appear to increase the risk of postoperative hemorrhage, and could reduce the risk of thromboembolism. Thus, appropriate postoperative resumption of anticoagulants or antiplatelets may be safe. Still, more evidence is needed to answer the question about whether and how to resume AT.
抗血栓药物(AT),包括抗凝剂和抗血小板药物,是慢性硬膜下血肿(CSDH)的危险因素。然而,此前文献中AT的使用与术后复发(PR)之间的关联并不明确。此外,AT恢复使用与术后并发症之间的关联也有待研究。检索了包括Pubmed、Embase和Cochrane在内的数据库,以查找正在服用抗凝剂或抗血小板药物且患有CSDH的患者。纳入了10项研究来分析AT的使用与PR之间的关联:荟萃分析表明,使用AT,包括抗凝剂(OR=2.20,95%CI[1.45,3.33];P=0.0002)和抗血小板药物(OR=1.64,95%CI[1.17,2.30];P=0.004),均可增加PR率。纳入了2项研究来分析AT恢复使用与术后并发症之间的关系。荟萃分析表明,服用AT的患者恢复用药后,PR风险并未增加(OR=0.33,95%Cl[0.13,0.80];P=0.01),且血栓栓塞事件的发生无统计学意义(OR=1.30,95%CI[0.26,6.50];P=0.75)。该荟萃分析表明,AT是CSDH复发的危险因素。恢复使用AT似乎不会增加术后出血风险,且可降低血栓栓塞风险。因此,术后适当恢复使用抗凝剂或抗血小板药物可能是安全的。不过,仍需要更多证据来回答是否以及如何恢复使用AT这一问题。